

## Release to Australian Securities Exchange

#### 19 June 2014

#### **Performance Rights**

Pursuant to its Long Term Incentive (LTI) Plan for Executives, the Company has issued 1,344,159 Performance Rights to be performance tested over the period to 1 October 2016. The performance period of LTIs is generally three years, however these LTIs have been granted with a shorter performance period to provide continuity of long term incentives to executives bearing in mind that no LTIs have been granted since October 2012.

An Appendix 3B is attached.

The performance measure for these Rights will be a comparison of the Company's shareholder value increase (measured as Total Shareholder Return) against the same measure for a comparator group consisting of companies in the S&P/ASX300, whereas the comparator group in relation to the performance measure that will be used for the previous issue of Rights, in October 2012, excludes companies which are in the Financial and Metals and Mining GICS sectors. Accordingly, a Long Term Incentives Plan Brochure that applies to the current grant of Performance Rights has been placed on the website.

For further information:

Ron Johnson Interim Chief Operating Officer ronj@redflex.com.au +61 3 9674 1754 Marilyn Stephens Company Secretary marilyn.stephens@redflex.com.au +61 3 9674 1712

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12$ 

Name of entity	
Name of entity	

ABN

96 069 306 216

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 \*Class of \*securities issued or to be issued Unlisted performance rights

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

1,344,159

Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Unlisted Performance rights issued pursuant to the Company's Long Term Incentive Plan for Executives, to be performance tested over the period to 1 October 2016.

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	No
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	1,344,159 unlisted Performance Rights issued pursuant to the Company's Long Term Incentive Plan for Executives, to be performance tested over the period to 1 October 2016.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the <sup>+</sup> securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	18 June 2014	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	110,762,310	Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9	Number and +class of all	
	+securities not quoted on ASX	
	(including the securities in section	
	2 if applicable)	

Number	+Class
2,824,092	Performance Rights
	Performance periods to:
	1 Oct 2014 – 764,633
	1 Oct 2015 – 715,300
	1 Oct 2016 – 1,344,159

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

## Part 2 - Bonus issue or pro rata issue

Not applicable		
	1 Is security holder approval required?	11
	2 Is the issue renounceable or non-renounceable?	12
	Ratio in which the *securities will be offered	13
	4 *Class of *securities to which the offer relates	14
	5 *Record date to determine entitlements	15
	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	16
	Policy for deciding entitlements in relation to fractions	17
	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	18
		19

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders*
25	If the issue is contingent on  +security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do +security holders dispose of their entitlements (except by sale through a broker)?

<sup>+</sup> See chapter 19 for defined terms.

App	endix	3B
New	issue	announcement

33	<sup>+</sup> Despa	patch date	
		Quotation of securities complete this section if you are applying for quotation of	f securities
34	Type of	of securities one)	
(a)		Securities described in Part 1	
(b)		All other securities  Example: restricted securities at the end of the escrowed period, p incentive share securities when restriction ends, securities issued on ex	
		at have ticked box 34(a) securities forming a new class of securities	
Tick to documer		te you are providing the information or	
35		If the *securities are *equity securities, the na additional *securities, and the number and perce those holders	
36		If the *securities are *equity securities, a dis* *securities setting out the number of holders in th 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	
37		A copy of any trust deed for the additional *secur	ities

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Company secretary	Date: 18 June 2014
Print name:	Marilyn Stephens	
	== == =	=====

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

(Not applicable)

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Add the following:	
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	
"A"	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1 "A" x 0.15  Note: number must be same as shown in Step 2	3"] to calculate remaining
Subtract "C"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.